CoChat

The gut–brain axis in early Parkinson’s disease: from prodrome to prevention

Open access
Oliver, Patrick James, Civitelli, Livia, Hu, Michele T. · 2025 · Journal of Neurology

The DOI matches its Crossref record; 275 of the 275 references it cites were found in a registry or an index; 107 of the 188 sources its claims cite were checked for support.

Abstract

Parkinson's disease is the second most common neurodegenerative disorder and fastest growing neurological condition worldwide, yet its etiology and progression remain poorly understood. This disorder is characterized pathologically by the prion-like spread of misfolded neuronal alpha-synuclein proteins in specific brain regions leading to Lewy body formation, neurodegeneration, and progressive neurological impairment. It is unclear what triggers Parkinson's and where α-synuclein protein aggregation begins, although proposed induction sites include the olfactory bulb and dorsal motor nucleus of the vagus nerve. Within the last 20 years, there has been increasing evidence that Parkinson's could be triggered by early microbiome changes and α-synuclein accumulation in the gastrointestinal system. Gut microbiota dysbiosis that alters gastrointestinal motility, permeability, and inflammation could enable prion-like spread of α-synuclein from the gut-to-brain via the enteric nervous system. Individuals with isolated rapid eye movement sleep behavior disorder have a high likelihood of developing Parkinson's and might represent a prodromal 'gut-first' subtype of the condition. The gut-first model of Parkinson's offers novel gut-based therapeutic avenues, such as anti-, pre-, and pro-biotic preparations and fecal microbiota transplants. Crucially, gut-based interventions offer an avenue to treat Parkinson's at early prodromal stages with the aim of mitigating evolution to clinically recognizable Parkinson's disease characterized by motor impairment.

Overview

CoChat Summary

## TL;DR

This is a narrative review arguing that Parkinson’s disease may begin in the gut in at least a subset of patients, especially those with prodromal rapid eye movement sleep behavior disorder (RBD), and that gut microbiome changes could help identify and treat disease earlier. The authors conclude that the gut-first model is promising but still largely speculative and needs prospective longitudinal and interventional studies.

## Key findings

  • Prodromal Parkinson’s disease is described as predominantly non-motor; the paper notes early constipation and gastrointestinal complaints in 80% of PD patients and states that RBD to overt α-synucleinopathies converts at 6.3% per year, with 73.5% converting after 12-year follow up.
  • The review says evidence is mixed for peripheral α-synuclein before brain involvement: some post-mortem and immunohistochemical studies found α-synuclein in the esophagus, stomach, small intestine, and enteric nervous system up to 20 years before diagnosis, but a large Arizona Parkinson’s consortium study did not find cases with enteric nervous system α-synuclein without central nervous system involvement.
  • It reports that gut microbiota dysbiosis is seen in prodromal PD, but study results are heterogeneous; sample sizes range from 38 in individual studies to 1269 in meta-analyses, and the authors say many studies are underpowered and confounded by geography, diet, smoking, medications, and other factors.
  • For treatment, the paper highlights gut-based interventions: it says 4 RCTs of fecal microbiota transplant (FMT) have available evidence, 3 reported changes in global or motor function, and 2 reported significant improvement in UPDRS scores at 12 weeks and 12 months, respectively.

## Methods

  • Narrative review synthesizing epidemiological, post-mortem, imaging, animal, and interventional studies on the gut–brain axis in early Parkinson’s disease.
  • Focuses on prodromal PD, especially RBD-positive and body-first phenotypes, and on gut microbiome findings from 16S rRNA studies, shotgun metagenomics, and related biomarker work.
  • No original dataset or primary statistical analysis is presented in the paper itself; it reviews and interprets prior studies.

## Limitations

  • The paper explicitly states that the current evidence for gut-first Parkinson’s disease remains “largely speculative” and that there are conflicting reports across microbiome, histopathology, and epidemiological studies.
  • It notes several limitations in the literature it reviews: small and heterogeneous samples, inadequate control of covariates, lack of a priori power calculations, limited species/strain resolution in 16S methods, and inconsistent bioinformatic/normalization approaches.
  • The text makes evident that this is a narrative synthesis rather than a systematic review or meta-analysis; therefore, its conclusions depend on the quality and selection of prior studies (this is inferred from the text).

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1007/s00415-025-13138-5

Cites

275 of 275 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 Temporal pathogenesis of brain- and body-first PD subtypes. A. In brain-first PD, α-synuclein aggregates are initially found in the olfactory bulb and propagate towards the substantia nigra before spreading to the rest of the body. B. In body-first PD, prodromal symptoms of constipation, RBD, orthostatic hypotension, and bladder problems occur up to 20 years before aggregates spread upwards to affect the dopaminergic neurons of the brainstem substantia nigra. This spread is thought to involve the vagus nerve (1), lymphatic system (2), and systemic circulation (3) to varying extents, utilizing mechanisms such as prion-like propagation and extracellular vesicles. C. Flowchart illustration of the pathophysiological sequence from gut dysbiosis to PD in body-first subtypes, identifying key events in disease initiation and progression. Amy, amygdala; DMV, dorsal motor nucleus of vagus; IML, intermediolateral column; LC, locus coeruleus; OB, olfactory bulb; SN, substantia nigra; ST, sympathetic trunk; Tox, transentorhinal cortex. (Created with BioRender.com)
Fig. 1 Temporal pathogenesis of brain- and body-first PD subtypes. A. In brain-first PD, α-synuclein aggregates are initially found in the olfactory bulb and propagate towards the substantia nigra before spreading to the rest of the body. B. In body-first PD, prodromal symptoms of constipation, RBD, orthostatic hypotension, and bladder problems occur up to 20 years before aggregates spread upwards to affect the dopaminergic neurons of the brainstem substantia nigra. This spread is thought to involve the vagus nerve (1), lymphatic system (2), and systemic circulation (3) to varying extents, utilizing mechanisms such as prion-like propagation and extracellular vesicles. C. Flowchart illustration of the pathophysiological sequence from gut dysbiosis to PD in body-first subtypes, identifying key events in disease initiation and progression. Amy, amygdala; DMV, dorsal motor nucleus of vagus; IML, intermediolateral column; LC, locus coeruleus; OB, olfactory bulb; SN, substantia nigra; ST, sympathetic trunk; Tox, transentorhinal cortex. (Created with BioRender.com)CC BY · PubMed Central
Fig. 2 Summary of the altered bacterial taxa and gastrointestinal properties observed in PD. In summary, there is an increase in pro-inflammatory and hydrogen sulfide producing bacteria, coupled with a decrease in anti-inflammatory and SCFA producing species. This drives a series of localized gastrointestinal and systemic changes seen in prodromal PD that enables the later development of clinically recognizable disease (Created with BioRender.com)
Fig. 2 Summary of the altered bacterial taxa and gastrointestinal properties observed in PD. In summary, there is an increase in pro-inflammatory and hydrogen sulfide producing bacteria, coupled with a decrease in anti-inflammatory and SCFA producing species. This drives a series of localized gastrointestinal and systemic changes seen in prodromal PD that enables the later development of clinically recognizable disease (Created with BioRender.com)CC BY · PubMed Central

Verification

Claims the paper makes

64 Valid · 9 Not valid · 31 Not checked · 42 Own results and interpretations

70 more claims · 37 with their cited sources checked

Create a free account to see all 146 claims and to verify the 21 references still open.

See all claims — free account
  • It may state two separate claims as one. 58
  • Probably not a substantial claim. 19

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Self-check results appear here once an independent check has confirmed them.

Cited works that were retracted

Works this paper cites that were later retracted, from the retraction notices publishers deposit. Major when the notice came out before this paper was published.

2 of 2

Citations

Cites

2 retracted

Show all 275 references

Research works printed but not linked: 1

  1. Huang B, Chau SW, Liu Y, Chan JW, Wang J, Ma SL, Zhang J, Chan PK, Yeoh YK, Chen Z (2023) Gut microbiome dysbiosis across early Parkinson’s disease, REM sleep behavior disorder and their first-degree relatives. Nature Commun 14(1):2501 · DOI · Paper page

Cited by

See all 42

Metadata

Authors
Oliver, P. J., Civitelli, L., & Hu, M. T.
Affiliations
  • University of Oxford (GB)
  • John Radcliffe Hospital (GB)
Corresponding author
Hu, Michele T.
Venue
Journal of Neurology
Published
2025-05-21
Volume
272
Issue
6
Pages
413-413
ISSN
  • 0012-1037 (ISSN-L)
  • 0340-5354
  • 1432-1459
OpenAlex
W4410514566
Cited by
42
References
272
Citations by year
2026: 32 · 2025: 10
FWCI
7.49
Type
journal article
Language
en
Open access
Licence
Locations
  • Journal of Neurology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
  • Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
Keywords
Parkinson's disease, gut-brain axis, gut dysbiosis, alpha-synuclein aggregation, prion-like spread, prodromal Parkinson's disease, REM sleep behavior disorder, enteric nervous system, probiotics, prebiotics, fecal microbiota transplantation, Lewy bodies, neurodegeneration, Parkinson's disease prevention
MeSH terms
Gastrointestinal Microbiome, Brain-Gut Axis, Animals, Brain, Humans, Parkinson Disease, alpha-Synuclein, Prodromal Symptoms, Dysbiosis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The gut–brain axis in early Parkinson’s disease: from prodrome to prevention. https://app.cochat.ai/papers/10.1007/s00415-025-13138-5
The paper
Oliver, P. J., Civitelli, L., & Hu, M. T. (2025). The gut–brain axis in early Parkinson’s disease: from prodrome to prevention. Journal of Neurology. https://doi.org/10.1007/s00415-025-13138-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.